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From May 1984 to August 1991, 58 patients without preoperative 
adjuvant therapy underwent resection of the esophagus for 
esophageal cancer. Three weeks after esophagectomy, one cycle of 
postoperative chemotherapy, consisting of intravenously infused 
cisplatinum at a dose of 70mg/m2 on day 1 and intramuscular 
pepleomycine at a dose of 5mg/body from day 1 to day 5, was 
administered in the 24 patients. In all patients receiving 
chemotherapy, mild fatigue or poor appetite occurred after drug 
administration, but severe drug toxicity, such as bone marrow 
depression, gastrointestinal bleeding or pulmonary fibrosis, did not 
occur. Eighteen patients (75%) died from cancer. The 3-year survival 
rate was 22.9% and the 5-year surival rate was 17.1%. In the patients 
who underwent curative operations, the 3-year and 5-year survival 
rates were 46.2% and 27.7%. However, there was no significant 
difference in the survival rates between the patients with 
postoperative chemotherapy and patients with esophagectomy alone. 
We conclude that one cycle of postoperative chemotherapy with 
cisplatinum and pepleomycin does not affect the survival of patients 
undergoing esophagectomy for esophageal cancer.
Introduction 
Esophageal carcinoma is a serious malignant disease with a 
poor prognosis, although a curative resection is more suc-
cessful in patients receiving preoperative radiation or che-
motherapy than in patients receiving only surgery. In 
patients with potentially resectable esophageal cancer, 
combined modality treatment is often performed after sur-
gical resection. In this study, we retrospectively evaluated 
the efficacy of postoperative chemotherapy for resectable 
esophageal cancer.
Materials and Methods 
Patients Selection and Evaluation 
From May 1984 to August 1991, 58 patients underwent 
esophagectomy without preoperative combined-modality 
treatment for potentially resectable and histologically prov-
en squamous cell carcinoma of the esophaqus. The patients
were retrospectively classified into two groups. Twenty-
four patients who had no complications, such as anasto-
motic leakage or prolonged ventilation support due to 
respiratory failure and who could start to consume food 
orally within 2 weeks after surgery, underwent postop-
erative chemotherapy (Group 1). Their performance status 
was above grade 3. Thirty-four patients did not undergo 
any postoperative combined-modality treatment, because 
these patients did not start eating within 2 weeks after 
surgery due to postoperative complications (Group 2). 
Their performance status was below grade 4. The charac-
teristics of the patients in the two groups are shown in 
Table 1.
Table 1. Characteristics of 58 Patients Undergoing Esophagecto-
my without Preoperative Combined-Modality Treatment
                        Postoperative No postoperative 
       Variables chemotherapy chemotherapy 
                      (n = 24) (n = 34)
Age 64.0 ± 8.3 66.3 ± 8.8 
Female/Male 5:19 2:32 
                         Number of patients (%)
Location of tumor 5(20 .8) 0 ( 0 ) Cervical esoph. 2 ( 8.3) 1 ( 2.9) Upper intrathoracic eso h. 7(29 .2) 24 (70.6) Middle intrathoracic esoph. 8(33 .3) 7(20.6) Lower intrathoracic esoph. 2 ( 8.3) 2 ( 5.9) Abdominal esoph. 
Lymph node metastasis 6(25 .0) 15 (44.1) Negative 
Positive 18 (75.0) 19 (55.9) 
Stage 0(0 ) 0(0 ) 
 Stage 0 0( 0 ) 7(20 .6)  Stage I 6(25 .0) 8(23.5)  Stage I IA 4(16 .7) 2 ( 5.9)  Stage 1113 
14 (58.3) 17 (50.0)  Stage III 
Curability 14 (58.3) 22 (64.7)  Curative resection 10 (41.7) 12 (35.3)  Palliative resection
Surgery 
In fifty-eight patients, thoracoabdominal esophagectomy
and reconstruction were performed with the gastric tube 
pulled up to the neck through the retrosternal route. In 
these patients, the cervical, posterior mediastinal and per-
igastric lymph nodes were dissected. 
Postoperative Chemotherapy 
Three weeks after surgery, one cycle of postoperative 
chemotherapy was administered, consisting of intrave-
nously infused cisplatinum (CDDP) at a dose of 70mg/m2 
on day 1 and intramuscular pepleomycine (PEP) at a dose 
of 5mg/body from day 1 to day 5. 
Data Analysis 
The survival rate was determined by the Kaplan-Meier 
method, and the Cox-Mantel method was used for statis-
tical evaluation of differences in survival rates, with a p 
value of 0.05 considered significant.
Results 
There were no significant differences in characteristics 
(Table 1) or in survival outcome (Table 2, Fig. 1-3) be-
tween patients with postoperative chemotherapy consisting 
of CDDP/PEP and those without combined modality treat-
ment. Eighteen patients (75%) died from cancer in Group 1 
and 18 (52.9%) in Group 2. The one-year cumulative 
survival rate was 47.6% in Group 1 and 50.6% in Group 2; 
the 3-year survival rates were 22.9% and 25.5%, respec-
Fig. 2. Cumulative survival curves by nodal involvement.
Table 2. Outcome in 58 patients followed from 1 to 8 years
                         Number of patients (%) 
      Outcome Postoperative No postoperative 
                      chemotherapy chemotherapy 
Alive (disease free) 6(2S.0) 10 (29.4) 
Cancer death 18(7S.0) 18(S2.9) 
Death from other disease 0 ( 0 ) 6(17.6)
Fig. 1. Overall cumulative survival curves. Fig. 3. Cumulative survival curves by curability.
tively, and the 5-year survival rates were 17.1% and 12.8%. 
In the patients who underwent curative operations, the 
3-year and 5-year survival rates were 46.2% and 27.7%, 
respectively in group 1 and 42.9% and 21.5% in Group 2. 
Hematogenic metastasis occurred in 8 patients (33.8%) in 
Group 1 and 7 (20.6%) in Group 2, lymphogenic metastasis 
in 1 (4.2%) and 2 (5.9%), respectively, and local recur-
rence in 4 (16.7%) and 4 (11.8%) in the two groups, 
respectively. In all patients receiving chemotherapy, mild 
fatigue or poor appetite occurred after drug administration, 
but severe drug toxicity, such as bone marrow depression, 
gastrointestinal bleeding or pulmonary fibrosis, did not 
occur.
Discussion 
In our institution, from 1970 to 1985 preoperative radiation 
had been administered in doses of from 35 to 50 Gy for 
resectable esophageal cancer, but prognosis of the patients 
had not improved comparing with patients of historical 
control. Some of nonrandmised studies (1, 2, 3, 4) sug-
gested no advantage for resectable esophageal cancer, and 
the optimal preoperative radiation is not clear. Therefore, 
principally postoperative chemotherapy was chosen for 
resectable esophageal cancer. Combination therapy of pe-
pleomycine and cisplatinum was adopted, because in the 
majority of our patients, histologic type of the esophageal 
cancer was squamous cell carcinoma. 
 Essentially, it should be analyzed to compare the sur-
vival by postoperative chemotherapy in the patients who 
are selected randomly. Although this study is not a random-
ized trial, it demonstrates that postoperative chemotherapy 
consisted of cisplatinum and pepleomycin may not be 
effective for resectable esophageal cancer. On the contrary, 
it may be bad for the survival in patients after esopha-
gectomy. 
 Recently, prospective randomized trials consisting of 
preoperative cisplatinum-based chemotherapy with con-
comitant radiation therapy were performed in some insti-
tutions (5, 6, 7, 8). These combined-modality therapy re-
sulted in pathologic complete responses in 20% to 40%. 
These results support the use of all three modalities as the 
optimal approach for the potential cure of esophageal 
cancer. However, because the number of patients was small 
and these study included both squamous cell carcinoma and 
adenocarcinoma, the results need to be confirmed and 
compared with esophagectomy alone. Furthermore, we 
should try a prospective randomized study, consisting of 
preoperative chemo-radiotherapy. 
  We conclude that one cycle of postoperative chemo-
therapy with cisplatinum and pepleomycin does not affect 
the survival of patients undergoing esophagectomy for 
esophageal cancer.
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